Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$54.88
+$0.11 · +0.20%
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Previous close
$54.88
+$0.11 · +0.20%
Pre-market
$54.98
+$0.10 · +0.18%
Oct 8, 6:16 AM ET
Regular session · ET · Market data may be delayed.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Day range
Current $54.88
52-week range
Current $54.88
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
75
Undervalued
Sentiment
68
Bullish
Risk
34
Moderate Risk
Momentum
70
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Day range
Current $54.88
52-week range
Current $54.88
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 79.95M USD | 39.01M USD | 31.64M USD | 21.25M USD | 21.83M USD |
| Cost of goods sold | 37.21M USD | 15.6M USD | 10.58M USD | 6.93M USD | 2.62M USD |
| Gross profit | 42.74M USD | 23.41M USD | 21.06M USD | 14.32M USD | 19.21M USD |
| Research and development | 7.77M USD | 3.26M USD | 3.32M USD | 4M USD | 6.24M USD |
| Selling, general, and administrative | 35.82M USD | 22.75M USD | 18.93M USD | 18.58M USD | 14.47M USD |
| Operating expenses | 42.67M USD | 26.01M USD | 22.25M USD | 22.58M USD | 20.7M USD |
| Interest expense | 4.78M USD | 2.01M USD | 1.06M USD | 955K USD | 1.04M USD |
| Depreciation and amortization | 4.04M USD | 1.15M USD | 901K USD | 1.77M USD | 462K USD |
| Operating income | 72K USD | −2.6M USD | −1.19M USD | −8.26M USD | −1.5M USD |
| Net income | −4.6M USD | −3.82M USD | −936K USD | −9.02M USD | −1.96M USD |
Company facts updated Oct 8, 2026.
Third-party consensus; not a GoAI recommendation.
Average target
$66.67
21.48% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI42.13M0.00%2.3T USD0.03%$381.03-0.40%
iShares Russell 2000 ETFIWM38.16M0.05%78.56B USD0.19%$277.7-1.29%
Vanguard Extended Market ETFVXF16.55M0.02%95.4B USD0.05%$233.49-1.56%
iShares Russell 2000 Growth ETFIWO13.7M0.10%14.25B USD0.24%$355.37-1.43%
State Street SPDR S&P Pharmaceuticals ETFXPH9.33M1.92%462.1M USD0.35%$62.910.00%
Vanguard Russell 2000 ETFVTWO9.28M0.05%18B USD0.06%$112.21-1.26%
Schwab U.S. Small-Cap ETFSCHA7.75M0.04%22.01B USD0.03%$32.61-1.47%
iShares Micro-Cap ETFIWC4.58M0.34%1.33B USD0.60%$183.36-1.09%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
